These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17564326)

  • 1. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
    Querfeld C; Kuzel TM; Guitart J; Rosen ST
    Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Kempf W
    Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
    Meisenheimer JL
    J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
    Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
    J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
    Kempf W; Kerl K; Mitteldorf C
    Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Management of CD30⁺ Lymphoproliferative Disorders.
    Hughey LC
    Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
    Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
    J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
    Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
    Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
    Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
    J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
    Paulli M; Berti E
    Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cutaneous CD30-positive lymphoproliferative disorders.
    Willemze R; Meijer CJ
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1319-32, vii-viii. PubMed ID: 14710887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.
    De Souza A; Carter JB; Harris NL; Ferry JA; Duncan LM
    J Cutan Pathol; 2015 Jul; 42(7):452-8. PubMed ID: 25931140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous CD30(+) lymphoproliferative disorders.
    Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
    J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
    Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
    Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
    Wieser I; Oh CW; Talpur R; Duvic M
    J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
    Kempf W
    J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathobiology of CD30+ cutaneous T-cell lymphomas.
    Kadin ME
    J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases.
    Kempf W; Kazakov DV; Palmedo G; Fraitag S; Schaerer L; Kutzner H
    Am J Surg Pathol; 2012 Jul; 36(7):1021-9. PubMed ID: 22472952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.